Good to see responsible interpretation of the data

StemCells, Inc. Announces Termination of Phase II Pathway Study Following Review of Data

NEWARK, Calif., May 31, 2016 (GLOBE NEWSWIRE) — StemCells, Inc. (NASDAQ: STEM) (the “Company”) today announced its decision to terminate the Company’s Phase II Pathway Study in spinal cord injury following an in-depth review of data from the study and after obtaining the concurrence of the study’s Interim Analysis Data Monitoring Committee (the “IA-DMC”).

Written by 

June 2013 – Present: Program Manager, Memorial Sloan-Kettering Cancer Center July 2009 – June 2012: iPierian, Senior Scientist & Project Team Leader January 2007 – June 2009: Postdoctoral fellow, University Health Network October 2003 – December 2006: Postdoctoral fellow, Mount Sinai School of Medicine